---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-100010"
form_type: "8-K"
ticker: "TOVX"
cik: "0000894158"
company_name: "Theriva Biologics, Inc."
filed_at: "2024-09-16T23:59:59+00:00"
generated_at: "2026-05-31T04:49:26.474294+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Theriva Biologics awarded €2.28M Spanish government funding for THERICEL cell platform

## Summary
- €1.33M unsecured loan lump sum in Q4 2024; interest 4.015%; repayable over 7 yrs after 3-yr grace.
- €0.95M grant to Universitat Autònoma de Barcelona paid in annual installments over 3 years.
- Funds to advance suspension cell platform for adenovirus/AAV therapies; scaling VCN-01 production.
- Award validates proprietary A549 suspension cell platform for clinical manufacturing.

## SEC filing metadata
- accession: 0001104659-24-100010
- form_type: 8-K
- ticker: TOVX
- cik: 0000894158
- company_name: Theriva Biologics, Inc.
- filed_at: 2024-09-16T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.03, 8.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/894158/000110465924100010/0001104659-24-100010-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/894158/000110465924100010/tm2424064d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-100010
- JSON: https://secwatch.observer/filing/0001104659-24-100010.json
- Plain text: https://secwatch.observer/filing/0001104659-24-100010.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.